Neurones (NRO) Q2 2026 earnings summary

Executive summary

• Achieved 7.2% revenue growth in the first half of 2026, with 6.9% organic growth, accelerating from 2025's 5.8% growth.

• Operating income rose 19.9% year-over-year, reaching 8.7% of revenue.

• Net income increased by 16.4% year-over-year, representing 6.9% of revenue.

Financial highlights

• H1 2026 revenue: €454.8M, up from €424.3M in H1 2025.

• Operating profit: €39.7M (8.7% margin) in H1 2026, up from €33.1M (7.8%) in H1 2025.

• Net profit after tax: €31.2M (6.9% margin) in H1 2026, up from €26.8M (6.3%) in H1 2025.

• Net cash (excluding IFRS 16 lease liabilities): €292.9M at June 30, 2026, up €10.7M after share repurchase and dividend payout.

Outlook and guidance

• Full-year 2026 revenue expected to exceed €900M.

• Operating income margin projected at approximately 9%.